Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A

Hemophilia A Clinical Trial

Official title:

Gene Therapy for Hemophilia A With a High Expression Factor VIII Transgene in Autologous Hematopoietic Stem Cells

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05265767
• Other study ID #: CSCR-CMC/FVIII LVGT/2018
• Status: Recruiting
• Phase: Phase 1
• Start date: April 1, 2022
• Est. completion date: January 1, 2039

Study information

• Verified date: March 2023
• Source: Christian Medical College, Vellore, India
• Contact: Christopher Benjamin, BPharm
• Phone: +914172224480
• Email: haemres[@]cmcvellore.ac.in
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Factor VIII (FVIII) is a large plasma glycoprotein that participates in blood coagulation. Loss of circulating FVIII activity due to mutations within the F8 gene results in the X-linked, recessive bleeding disorder hemophilia A. The clinical presentation ranges from a mild to severe bleeding phenotype that correlates with the patient's residual plasma FVIII activity level. Current state of the art treatment entails frequent infusion of FVIII protein. However, several limitations remain to treating hemophilia A, which are 1) access to FVIII-replacement products (currently <30% of the world population is treated adequately, access is highly restricted in India), 2) high burden of compliance with treatment protocols particularly in children 3) the expense of FVIII-replacement products, 4) the development of humoral anti-FVIII immune responses that block FVIII activity and limit treatment efficacy and 5) morbidity due to crippling musculoskeletal disease when inadequately treated. Several newer hemostasis agents are being developed but like the recombinant Clotting Factor Concentrate (CFC) from the 1990s, these are also not likely to be made available in India for many years. Currently, the only cure for hemophilia A is orthotopic liver transplantation.

Description:

Eligible subjects will undergo (Cluster of Differentiation) CD34+ hematopoietic stem cell collection. These cells will be transduced ex vivo with (Cluster of Differentiation) CD68-ET3 lentiviral vector and subsequently, following a conditioning regimen, the transduced cells will be infused to patients. After completion of study treatment, patients are followed up periodically for up to 15 years.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 9
• Est. completion date: January 1, 2039
• Est. primary completion date: January 1, 2025
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Able to provide informed consent for the protocol approved by the Institutional Review Board.
• Male subjects who are =18 years of age and < 45 years of age.
• Diagnosis of severe hemophilia A (<1 IU/dl factor VIII activity).
• Documented history of more than 100 exposures of factor VIII treatment.
• Average of at least 3 bleeds requiring treatment per year over the prior three years, at least 3 bleeds per year during the 3 years preceding the initiation of prophylaxis, or evidence of joint damage (knee, elbow or ankle) on physical or radiographic examination thought to be related to hemophilia.
• Performance status (Karnofsky score) of at least 70.
• Willing and able to comply with the requirements of the protocol.

Exclusion Criteria:

• History of spontaneous central nervous system bleeding within the last 5 years.
• Significant organ dysfunction which could interfere with outcome of therapy such as: -
• Cardiac: There should be no evidence of significant cardiac dysfunction (resting left ventricular ejection fraction of < 50%) and no cardiomegaly. There should not be uncontrollable hypertension.
• Renal: Glomerular Filtration Rate (GFR) < 60 ml/min/1.73m2 as calculated using the Cockcroft-Gault equation.
• Hepatic: There should be no evidence of hepatic dysfunction which is defined as a serum bilirubin of > 1.5 mg/dl and Aspartate Amino Transferase (AST) / Alanine Amino Transferase (ALT) > 3X the upper limit of normal,
• Hematologic: Absolute neutrophil counts (ANC) < 1000/mm3 and platelets counts < 150,000/µL.
• Pulmonary function with a corrected Diffusing Capacity of lung for Carbon Monoxide (DLCO) of < 50% predicted
• History of a FVIII inhibitor (>0.6 Bethesda Units/ml) including at least 2 measurements over the preceding 5 years or any single titer >5 Bethesda Units (BU) /ml.
• Previous stem cell transplant.
• HIV positive.
• Evidence of hepatitis B active infection or chronic carrier
• Evidence of chronic hepatitis C infection. Absence of chronic infection will be documented with at least 2 negative viral loads at least 6 months apart.
• Diagnosis of a bleeding disorder other than hemophilia A
• Use of medication(s) that can affect hemostasis (e.g. aspirin and non- cyclooxygenase (COX-2) selective non-steroid anti-inflammatory drugs).
• History of cancer or familial cancer syndromes
• Any condition in the opinion of the principle investigator that will negatively impact the subject's ability to safely undergo an autologous stem cell transplant.
• Any reason in the opinion of the principle investigator that will negatively impact the subject's ability to complete the clinical trial per the trial protocol.

Related Conditions & MeSH terms

• Hemophilia A

Intervention

Biological:
• Auto CD34+PBSC transduced with a lentiviral vector encoding a novel coagulation factor VIII transgene
Auto CD34+PBSC transduced with a lentiviral vector encoding a novel coagulation factor VIII transgene administered by IV infusion following conditioning regimen.

Locations

Country	Name	City	State
India	Christian Medical College Vellore Ranipet Campus	Vellore	Tamil Nadu

Sponsors (2)

Lead Sponsor	Collaborator
Christian Medical College, Vellore, India	Dr. H. Trent Spencer, Professor, Emory University of Medicine, Atlanta Ga, 30322

Country where clinical trial is conducted

India, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Annualized bleed rate (ABR) assessed by number of bleeding episodes and in comparison to before gene therapy.	To evaluate the impact of autologous HSCT with CD68-ET3-LV CD34+ on annualized bleed rate.	Assessement of Annualized bleeding rate (ABR) through long term follow-up for up to 15 years
Primary	Number of study participants experiencing serious adverse events (SAEs) following treatment through 12 weeks.	As assessed by physical examination, vital signs, clinical labs, and FVIII inhibitor levels (Bethesda assay). Serious adverse event (SAE) is an AE resulting in any of the following outcomes: death; Life-threatening event; Required or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly.	Percentage of patients experiencing SAEs following 12 weeks of treatment
Primary	Severity of serious adverse events following administration of CD68-ET3-LV CD34+ as assessed by NCI Common Toxicity Criteria for Adverse Events (CTCAE) Version 5.0.	Serious adverse events severity assessment	Assessement of severity of SAE through 12 weeks after treatment
Primary	Duration of the serious adverse events following administration of CD68-ET3-LV CD34+.	As assessed by stop and end dates of the SAEs	Assessment of duration of SAEs after 12 weeks of treatment
Secondary	Time to absolute neutrophil count (ANC) recovery.	Time to ANC recovery (the first day a neutrophil count is >0.5 x 109/L (>500/µL) on three consecutive days) following busulfan/ anti-thymocyte globulin conditioning and infusion of autologous CD34+ hematopoietic stem and progenitor cells (HSPC) transduced with CD68-ET3-LV.	Measurement of ANC upto 5 years
Secondary	Time to platelet recovery	Time to platelet recovery (the first day a platelet count is > 50,000/µL on three consecutive days without platelet transfusions during the prior 7 days) following infusion of autologous CD34+ cells transduced with CD68-ET3-LV.	Measured of platelet recovery upto 5 years
Secondary	Anti-human factor VIII inhibitor titer	Assessed via Bethesda assay	Measured of FVIII inhibitor titer upto 5 years
Secondary	Immune response to ET3 as measured by modified Bethesda assay incorporating ET3i spiked into FVIII-deficient plasma	Immune response to ET3	Measured of Immune response to ET3 for up to 5 years
Secondary	Vector copy number of circulating genetically modified cells as determined by real time Polymerase Chain Reaction (PCR)	Vector copy number determined via real time PCR	Measured of Vector copy number by PCR upto 5 years
Secondary	To evaluate FVIII activity after Autologous Hematopoietic Stem Cell Transplantation (HSCT) with CD68ET3-LV transduced CD34+ cells through measurement of plasma FVIII activity levels.	Evaluate FVIII activity	Measurement of FVIII activity (assay) upto 5 years
Secondary	To evaluate the impact of autologous HSCT with CD68ET3-LV transduced CD34+ cells on bleeding phenotype as measured by frequency of bleeding episodes and clotting factor concentrate (CFC) usage.	Evaluate the impact of autologous HSCT with CD68ET3-LV transduced CD34+ cells	Measured of frequency of bleeding episodes and CFC usage upto 5 years
Secondary	To evaluate the relationship between FVIII activity level and engraftment of CD68ET3-LV modified cells.	Evaluate correlation between FVIII activity in % level and engraftment of ANC measured in per cubic milliliter (cumm) Platelets values in per cumm	Evaluation of relationship between FVIII activity and engraftment upto 5 years